Good Care
For Psoriatic Arthritis
Recent progress in understanding the course of psoriatic arthritis (PsA) has lead to breakthroughs in therapies. Yet the needs of many people living with PsA are still unmet. Through this project, IFPA aims to join forces with rheumatologists and the patient community to raise awareness of new treatment guidelines, and ultimately improve quality of life for people with PsA around the world.
Downloadable interactive Patient Checklist and Illustration booklets for your treatment
tool Toolkits
Patient Checklist for Psoriatic Arthritis Visit _with notes placeholder
tool Toolkits
Patient Checklist form for your Psoriatic Arthritis Visit _for your doctor
Do you feel confident discussing treatment guidelines with your healthcare provider?
The new GRAPPA guidelines (2022) assign equal importance to each clinical symptom (also called domains) and comorbidities.
What do the current GRAPPA recommendations advocate for?
- The difference in points assigned to each symptom strongly impacts therapeutic choice.
- The ultimate goal of therapy is to achieve the lowest possible level of disease activity in all domains of the disease.
- Click to view guidelines : Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
Why is this important?
- The current treatment guidelines take into consideration previous therapies, and associated comorbities that impact the quality of life to support therapy decision-making.
- IFPA is looking to co-create educational materials based on the latest evidence that is useful to people living with PsA theire care-givers and Health Care providers.
- The project team welcomes you to participate in a webinar to mark the materials launch.
This project is supported by
UCB Pharma has provided financial support through an unrestricted grant for the delivery of the First phase of the Psoriatic Arthritis Awareness project, also known as the "Good Care for the Psoriatic Arthritis" Project. UCB Pharma had no influence or input over the content, including the selection of project members and the development of all associated assets, such as videos, podcasts, and articles. The support from UCB Pharma was solely in the form of an unrestricted grant.
Sign up to our newsletter